You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Alan W. Schoenbart | 774,500 | 0 | 774,500 | 0 | 774,500 | 5.6% |
Page 1 of 4 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d – 102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED
PURSUANT
TO RULE 13d-2(a)
ECHO
THERAPEUTICS, INC.
THERAPEUTICS, INC.
(Name of Issuer)
Common
Stock, par value $.01 per share
Stock, par value $.01 per share
(Title of Class of Securities)
27876L107
(CUSIP Number)
Kevin
W. Waite, Esq.
W. Waite, Esq.
Moomjian,
Waite, Wactlar & Coleman, LLP
Waite, Wactlar & Coleman, LLP
100
Jericho Quadrangle, Suite 208
Jericho Quadrangle, Suite 208
Jericho,
New York 11753
New York 11753
(516)
937-5900
937-5900
(Name, Address and Telephone Number of Person Authorized
to
Receive Notices and Communications)
March
21, 2017
21, 2017
(Date of Event which Requires Filing of this
Statement)
If the
filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D,
and is filing this schedule because of Rule 13d-1(e), 13d-1(f), or
13d-1(g), check the following box [ ].
filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D,
and is filing this schedule because of Rule 13d-1(e), 13d-1(f), or
13d-1(g), check the following box [ ].
NOTE:
Schedules filed in paper format shall include a signed original and
five copies of the schedule, including all exhibits. See Rule
13d-7(b) for other parties to whom copies are to be
sent.
Schedules filed in paper format shall include a signed original and
five copies of the schedule, including all exhibits. See Rule
13d-7(b) for other parties to whom copies are to be
sent.
*The
remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing
information which would alter disclosure provided in a prior cover
page.
remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing
information which would alter disclosure provided in a prior cover
page.
The
information required on the remainder of this cover page shall not
be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 (“Act”) or
otherwise subject to the liabilities of that Section of the Act but
shall be subject to all other provisions of the Act (however, see
the Notes).
information required on the remainder of this cover page shall not
be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 (“Act”) or
otherwise subject to the liabilities of that Section of the Act but
shall be subject to all other provisions of the Act (however, see
the Notes).
Follow Echo Therapeutics Inc. (NASDAQ:ECTE)
Follow Echo Therapeutics Inc. (NASDAQ:ECTE)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 4
